One-year outcomes in a multicentre cohort study of incident rare diffuse parenchymal lung disease in children (ChILD)

ChILDEU study group; Steve Cunningham; Catriona Graham; Morag MacLean; Paul Aurora; Michael Ashworth; Angelo Barbato; Alistair Calder; Julia Carlens; Annick Clement; Meike Hengst; Birgit Kammer; Nural Kiper; Katarzyna Krenke; Kai Kronfield; Joanna Lange; Julia Ley-Zaporozhan; Andrew G Nicholson; Simone Reu; Traudl Wesselak; Martin Wetzke; Andrew Bush; Nicolaus Schwerk; Matthias Griese

doi:10.1136/thoraxjnl-2019-213217

One-year outcomes in a multicentre cohort study of incident rare diffuse parenchymal lung disease in children (ChILD)

ChILDEU study group, Steve Cunningham, Catriona Graham, Morag MacLean, Paul Aurora, Michael Ashworth, Angelo Barbato, Alistair Calder, Julia Carlens, Annick Clement, Meike Hengst, Birgit Kammer, Nural Kiper, Katarzyna Krenke, Kai Kronfield, Joanna Lange, Julia Ley-Zaporozhan , Andrew G Nicholson, Simone Reu, Traudl WesselakMartin Wetzke, Andrew Bush, Nicolaus Schwerk, Matthias Griese

Research output: Contribution to journal › Article › peer-review

Abstract

We performed a prospective, observational, cohort study of children newly diagnosed with children’s interstitial lung disease (ChILD), with structured follow-up at 4, 8, 12 weeks and 6 and 12 months. 127 children, median age 0.9 (IQR 0.3–7.9) years had dyspnoea (68%, 69/102), tachypnoea (75%, 77/103) and low oxygen saturation (SpO2) median 92% (IQR 88–96). Death (n=20, 16%) was the most common in those <6 months of age with SpO2<94% and developmental/surfactant disorders. We report for the first time that ChILD survivors improved multiple clinical parameters within 8–12 weeks of diagnosis. These data can inform family discussions and support clinical trial measurements.

Original language	English
Pages (from-to)	172-175
Journal	Thorax
Volume	75
Issue number	2
Early online date	20 Nov 2019
DOIs	https://doi.org/10.1136/thoraxjnl-2019-213217
Publication status	Published - Feb 2020

Access to Document

10.1136/thoraxjnl-2019-213217

Accepted_Manuscript
This is the author's peer reviewed manuscript as accepted for publication.
Accepted author manuscript, 272 KB

Orphans Unite: chILD better together European Management Platform for Childhood Interstitial Lung Diseases
Cunningham, S.
EU government bodies
1/12/12 → 30/11/16
Project: Research

Steve Cunningham
- Deanery of Clinical Sciences - Professor of Paediatric Respiratory Medicine
- MRC Centre for Reproductive Health
- Centre for Inflammation Research
Person: Academic: Research Active

Cite this

ChILDEU study group, Cunningham, S., Graham, C., MacLean, M., Aurora, P., Ashworth, M., Barbato, A., Calder, A., Carlens, J., Clement, A., Hengst, M., Kammer, B., Kiper, N., Krenke, K., Kronfield, K., Lange, J., Ley-Zaporozhan , J., Nicholson, A. G., Reu, S., ... Griese, M. (2020). One-year outcomes in a multicentre cohort study of incident rare diffuse parenchymal lung disease in children (ChILD). Thorax, 75(2), 172-175. https://doi.org/10.1136/thoraxjnl-2019-213217

@article{ff0e938a4b2f411b8d9032afcc51321e,

title = "One-year outcomes in a multicentre cohort study of incident rare diffuse parenchymal lung disease in children (ChILD)",

abstract = "We performed a prospective, observational, cohort study of children newly diagnosed with children{\textquoteright}s interstitial lung disease (ChILD), with structured follow-up at 4, 8, 12 weeks and 6 and 12 months. 127 children, median age 0.9 (IQR 0.3–7.9) years had dyspnoea (68%, 69/102), tachypnoea (75%, 77/103) and low oxygen saturation (SpO2) median 92% (IQR 88–96). Death (n=20, 16%) was the most common in those <6 months of age with SpO2<94% and developmental/surfactant disorders. We report for the first time that ChILD survivors improved multiple clinical parameters within 8–12 weeks of diagnosis. These data can inform family discussions and support clinical trial measurements.",

author = "{ChILDEU study group} and Steve Cunningham and Catriona Graham and Morag MacLean and Paul Aurora and Michael Ashworth and Angelo Barbato and Alistair Calder and Julia Carlens and Annick Clement and Meike Hengst and Birgit Kammer and Nural Kiper and Katarzyna Krenke and Kai Kronfield and Joanna Lange and Julia Ley-Zaporozhan and Nicholson, {Andrew G} and Simone Reu and Traudl Wesselak and Martin Wetzke and Andrew Bush and Nicolaus Schwerk and Matthias Griese",

year = "2020",

month = feb,

doi = "10.1136/thoraxjnl-2019-213217",

language = "English",

volume = "75",

pages = "172--175",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "2",

}

ChILDEU study group, Cunningham, S, Graham, C, MacLean, M, Aurora, P, Ashworth, M, Barbato, A, Calder, A, Carlens, J, Clement, A, Hengst, M, Kammer, B, Kiper, N, Krenke, K, Kronfield, K, Lange, J, Ley-Zaporozhan , J, Nicholson, AG, Reu, S, Wesselak, T, Wetzke, M, Bush, A, Schwerk, N & Griese, M 2020, 'One-year outcomes in a multicentre cohort study of incident rare diffuse parenchymal lung disease in children (ChILD)', Thorax, vol. 75, no. 2, pp. 172-175. https://doi.org/10.1136/thoraxjnl-2019-213217

TY - JOUR

T1 - One-year outcomes in a multicentre cohort study of incident rare diffuse parenchymal lung disease in children (ChILD)

AU - ChILDEU study group

AU - Cunningham, Steve

AU - Graham, Catriona

AU - MacLean, Morag

AU - Aurora, Paul

AU - Ashworth, Michael

AU - Barbato, Angelo

AU - Calder, Alistair

AU - Carlens, Julia

AU - Clement, Annick

AU - Hengst, Meike

AU - Kammer, Birgit

AU - Kiper, Nural

AU - Krenke, Katarzyna

AU - Kronfield, Kai

AU - Lange, Joanna

AU - Ley-Zaporozhan , Julia

AU - Nicholson, Andrew G

AU - Reu, Simone

AU - Wesselak, Traudl

AU - Wetzke, Martin

AU - Bush, Andrew

AU - Schwerk, Nicolaus

AU - Griese, Matthias

PY - 2020/2

Y1 - 2020/2

N2 - We performed a prospective, observational, cohort study of children newly diagnosed with children’s interstitial lung disease (ChILD), with structured follow-up at 4, 8, 12 weeks and 6 and 12 months. 127 children, median age 0.9 (IQR 0.3–7.9) years had dyspnoea (68%, 69/102), tachypnoea (75%, 77/103) and low oxygen saturation (SpO2) median 92% (IQR 88–96). Death (n=20, 16%) was the most common in those <6 months of age with SpO2<94% and developmental/surfactant disorders. We report for the first time that ChILD survivors improved multiple clinical parameters within 8–12 weeks of diagnosis. These data can inform family discussions and support clinical trial measurements.

AB - We performed a prospective, observational, cohort study of children newly diagnosed with children’s interstitial lung disease (ChILD), with structured follow-up at 4, 8, 12 weeks and 6 and 12 months. 127 children, median age 0.9 (IQR 0.3–7.9) years had dyspnoea (68%, 69/102), tachypnoea (75%, 77/103) and low oxygen saturation (SpO2) median 92% (IQR 88–96). Death (n=20, 16%) was the most common in those <6 months of age with SpO2<94% and developmental/surfactant disorders. We report for the first time that ChILD survivors improved multiple clinical parameters within 8–12 weeks of diagnosis. These data can inform family discussions and support clinical trial measurements.

U2 - 10.1136/thoraxjnl-2019-213217

DO - 10.1136/thoraxjnl-2019-213217

M3 - Article

VL - 75

SP - 172

EP - 175

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 2

ER -

One-year outcomes in a multicentre cohort study of incident rare diffuse parenchymal lung disease in children (ChILD)

Abstract

Access to Document

Fingerprint

Projects

Orphans Unite: chILD better together European Management Platform for Childhood Interstitial Lung Diseases

Profiles

Steve Cunningham

Cite this